PCG
NTLA icon

Private Capital Group’s Intellia Therapeutics NTLA Stock Holding History

Private Capital Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Sell
21
-59
-74% -$3K ﹤0.01% 1743
2022
Q1 		$6K Sell
80
-1
-1% -$85 ﹤0.01% 1460
2021
Q4 		$10K Sell
81
-10
-11% -$1.25K ﹤0.01% 1293
2021
Q3 		$12K Buy
91
+70
+333% +$10.6K ﹤0.01% 1273
2021
Q2 		$3K Buy
+21
New +$1.64K ﹤0.01% 1737

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Private Capital Group's NTLA Position: Q2 2022 in Review

Private Capital Group reduced its Intellia Therapeutics (NTLA) stake by 74% in Q2 2022, selling an estimated $3K and leaving 21 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Private Capital Group first reported a position in NTLA in Q2 2021 and has held it in 5 quarters since. The position peaked at $12K in Q3 2021. 301 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Private Capital Group held 21 shares of Intellia Therapeutics worth $1K as of Q2 2022.
  • Private Capital Group sold 59 Intellia Therapeutics shares in Q2 2022, an estimated $3K.
  • Intellia Therapeutics made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1743 holding.
  • Private Capital Group first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Private Capital Group's Intellia Therapeutics position peaked at $12K in Q3 2021.
  • 301 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.